E1609 III期研究:辅助伊匹木单抗3或10 mg/kg对比高剂量干扰素α-2b治疗已切除高危黑色素瘤
E1609是一项III期随机试验,纳入1670例已切除高危皮肤黑色素瘤患者,比较伊匹木单抗3 mg/kg(ipi3)、10 mg/kg(ipi10)与高剂量干扰素α-2b(HDI)的疗效与安全性。ipi3对比HDI显示总生存(OS)显著获益(HR 0.78;95.6% CI 0.61-0.99;
要点
- 辅助ipi3对比HDI显著改善OS,为黑色素瘤辅助治疗首次在活性对照下显示OS获益。
- 已获批的辅助剂量ipi10毒性更高,疗效未优于HDI。
- ipi3组≥3级治疗相关不良事件发生率37%,低于HDI的79%和ipi10的58%。
核心结论
- 辅助伊匹木单抗3 mg/kg对比高剂量干扰素α-2b显著改善已切除高危黑色素瘤患者的总生存。
- 已获批的辅助伊匹木单抗10 mg/kg毒性更高,疗效未优于高剂量干扰素α-2b。
研究设计与样本
- E1609是一项III期试验,纳入已切除皮肤黑色素瘤患者(AJCC第7版IIIB、IIIC、M1a或M1b期)。
- 2011年5月至2014年8月,1670例成人患者按1:1:1中央随机分配至ipi3组(n=523)、HDI组(n=636)或ipi10组(n=511)。
- 研究设两个共同主要终点:总生存(OS)和无复发生存(RFS),采用两步分层法先比较ipi3对比HDI,再比较ipi10对比HDI。
主要发现
- ipi10对比HDI(n=989)的趋势有利于ipi10但未达统计学显著。
- ≥3级治疗相关不良事件发生率:ipi3组37%、HDI组79%、ipi10组58%;导致治疗中止的不良事件发生率分别为35%、20%和54%。
临床怎么用
- 对于已切除高危黑色素瘤,辅助伊匹木单抗3 mg/kg可作为对比高剂量干扰素α-2b的生存获益选择。
- 已获批的辅助伊匹木单抗10 mg/kg毒性更高且疗效未优于高剂量干扰素α-2b,临床选择时需权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ipi10 versus HDI. PATIENTS AND METHODS: E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b). It had 2 coprimary end points: OS and RFS. A 2-step hierarchic approach first evaluated ipi3 versus HDI followed by ipi10 versus HDI. RESULTS: Between May 2011 and August 2014, 1,670 adult patients were centrally randomly assigned (1:1:1) to ipi3 (n = 523), HDI (n = 636), or ipi10 (n = 511). Treatment-related adverse events grade ≥ 3 occurred in 37% of patients receiving ipi3, 79% receiving HDI, and 58% receiving ipi10, with adverse events leading to treatment discontinuation in 35%, 20%, and 54%, respectively. Comparison of ipi3 versus HDI used an intent-to-treat analysis of concurrently randomly assigned patient cases (n = 1,051) and showed significant OS difference in favor of ipi3 (hazard ratio [HR], 0.78; 95.6% repeated CI, 0.61 to 0.99; P = .044; RFS: HR, 0.85; 99.4% CI, 0.66 to 1.09; P = .065). In the second step, for ipi10 versus HDI (n = 989), trends in favor of ipi10 did not achieve statistical significance. Salvage patterns after melanoma relapse showed significantly higher rates of ipilimumab and ipilimumab/anti-programmed death 1 use in the HDI arm versus ipi3 and ipi10 (P ≤ .001). CONCLUSION: Adjuvant therapy with ipi3 benefits survival versus HDI; for the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant improvement in OS against an active control regimen. The currently approved adjuvant ipilimumab dose (ipi10) was more toxic and not superior in efficacy to HDI.
引用
- Tarhini AA, Lee SJ, Hodi FS, et al. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2019. PMID: 31880964. doi:10.1200/JCO.19.01381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。